News Has trial result burst BMS' Cobenfy bubble? Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.
News Failed trial knocks back wider use of BMS' Camzyos Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.
News BMS gets another FDA okay for Opdivo/Yervoy combo Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.
News BMS bags a double-quick colorectal cancer approval from FDA The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer.
News BMS absorbs CAR-T partner 2seventy bio for $286m Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.
News J&J shows its confidence in oral IL-23 drug for psoriasis J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.
News Roche gets EU okay for chest pain algorithm Roche has claimed a CE Mark in the EU for an AI algorithm that can help doctors decide whether patients with chest pain are having a heart attack.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl